04.10-11.24-HST-Startups-Zeta-Surgical

HIEU LE MAU: Good morning. Thanks for joining me today. My name is Hieu Le Mau, director of operations at Zeta Surgical. Our company is a tech company headquartered at Boston. The company was founded by Harvard and MIT faculty and alumni and is backed by top VCs such as Y Combinator.

I'm sure everyone here is familiar with the GPS system in your phone that you use with a Google map to travel to your work every day. Navigation is GPS-like in surgeries. The surgeons use navigation to guide the instrument to a specific internal target. However, with the current technology, the applications are very limited, usually being constrained in the operating room, and is only accessible in a very few select cases. The other aims to solve the problems by developing a navigation system that can be deployed in a wide variety of procedures and across any point of care.

Zeta Navigation System is FDA cleared, completed first in human, and is rolling out commercially in the US. The technology relies on computer vision and AI to provide real-time navigation with best-in-class accuracy and can be deployed very quickly under five minutes. Leveraging the technology, we are developing the robotic system Nexus and also the ZetaFUS, which is a noninvasive drug delivery system.

Let me focus a little bit on the ZetaFUS. this System aims to disrupt the blood-brain barrier to allow the entry of the large drugs into the brain. And this technology uses the focused ultrasound. This technology can be deployed by the bed on [? wet ?] patients and in any hospital environments.

We view Zeta as the catalyst for a new wave of targeted therapies, and it has a huge market, including brain cancer, brain tumor, depression, Alzheimer's, and many others. Aside from the clinical values, we believe that Zeta is valuable to hospitals that are pursuing value-based care as well. We actually have a lot of interest from the hospital administrators.

We are also launching the first paid pilot with MGH in the next few months. If you are interested to find out more about our technology or how we perform the accuracy testing, refer to our published papers.

We have successfully completed our first in-human clinical study for EVD procedures in Singapore, in Tan Tock Seng and Singapore General Hospital. The results show significant improvement compared to the current standard of care, which is by freehand. We achieved 100% ideal placement without any complications.

On the regulatory roadmap, the Zeta Navigation System was cleared by the FDA in 2023. And we are looking to expand our regulatory applications to more countries and more indications in the next two years. We also plan to file for FDA applications for the Nexus Robotic System and ZetaFUS Drug Delivery System later this year and early in 2025.

We are looking to have a partnership with hospital, medtech communities, and pharma communities, especially with the ZetaFUS system to deliver drugs. Thank you for joining me today.

[APPLAUSE]